What's missing in pharma cardiac safety today: mechanism on proprietary compounds, in the cell types pharma actually screens against. Open atlases can't include your proprietary compounds. Internal hERG and CiPA flag risk; they don't deliver mechanism. Generic CROs execute; they don't iterate.
For pharma cardiac safety, each engagement runs as a closed-loop research program in human iPSC-cardiomyocytes: AI-orchestrated experimental design, cloud-lab execution (Arctoris), multimodal mechanism profiling (Cell Painting + DRUG-seq + electrophysiology), active learning across 2–3 cycles within a 4–8 week window. NDA-protected.
The same engine extends to academic functional genomics (allele-specific perturbation screens, dominant-disease mechanism studies), AI-bio research, and other molecular biology questions needing iterative, multimodal work.
What hERG can't tell you
Mechanism. Off-target liabilities. Pathway-level disruption. Multimodal readouts on your compound in iPSC-cardiomyocytes, not just a binary risk flag.
What generic CROs can't do
Iterate. Each round of data trains the model that picks the next round. 2–3 active-learning cycles inside a 4–8 week engagement.
What open data won't have
Your compound. NDA-protected from intake to delivery. Methods accrue to the engine; compound-specific findings stay yours.
Calibration
Your first engagement runs as a calibration. You send compounds with known cardiac outcomes (clinical-positive and clinical-negative), blinded to us until delivery. We return mechanism profiles plus a fine-tuned model you keep. Low commitment to find out where the engine works on your chemistry before you scale up. NDA-protected.
Founded by
Daniel Reda. Two prior exits in life science data: CureTogether (acquired by 23andMe) and Redasoft (acquired by Hitachi). Background in Molecular Genetics.
Scientific Advisory Board forming.